Hypercholesterolemia and Lipid-Lowering Therapy in Children and Adolescents With Type 1 Diabetes: Do We Implement Current Guidelines?
Authors' conclusion
We found a high prevalence of LDL hypercholesterolemia. The use of LLM was low, despite treatment indication, and treatment targets were mostly not achieved either due to underdosing or nonadherence to LLM. These findings confirm that dyslipidemia remains an underestimated cardiovascular risk factor in pediatric diabetology.
Study context
- Population
- Youth <18 years with T1D and ≥1 documented LDL measurement, DPV registry 2013–2023
- Participants
- 55,028 participants
- Outcome
- Prevalence of elevated LDL cholesterol
Methodological detailsregistry-based (DPV)
- Registry-based (DPV)
Main finding
As reported in the abstract
Prevalence of elevated LDL
LDL >3.4 mmol/L
9.7%
LDL >4.1 mmol/L
2.3%
Observational data: associations, not effects.
Further findings
Factors with strongest effect on LDL levels (linear regression)
- HbA1c
- β = 1,142.7; P = 0.001
- Female sex
- β = 861.5; P < 0.001
- BMI >70th percentile
- β = 520.1; P < 0.001
Lipid-lowering medication (LLM) use
- Received LLM among those with elevated LDL
- 7.3%
- Not treated, LDL >3.4 mmol/L
- 92.7%
- Not treated, LDL >4.1 mmol/L
- 87.0%
Factors associated with LLM use (OR, 95% CI)
- LDL >4.1 mmol/L
- 19.13 (15.4-23.7)
- Age 12-18 years
- 3.1 (1.82-5.41)
- Diabetes duration 5-10 years
- 2.31 (1.9-2.1)
- BMI >70th percentile
- 1.8 (1.5-2.1)
- HbA1c >9%
- 1.3 (1.0-1.6)
- Female sex
- 1.18 (1.0-1.4)
LDL target achievement among treated (n = 707)
- Reached LDL <2.6 mmol/L
- 15.7%
- LDL remained >3.4 mmol/L
- 55%
Original publication
Hypercholesterolemia and Lipid-Lowering Therapy in Children and Adolescents With Type 1 Diabetes: Do We Implement Current Guidelines? Diabetes Care. Published 17 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →